Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Gregory Norden Biography and Net Worth

Director of Zoetis

Gregory Norden is the former Chief Financial Officer of Wyeth and has been a member of our board since January 2013. Mr. Norden also serves on the Boards of NanoString Technologies, a leading provider of life science tools for translational research; Praxis, a clinical stage biopharmaceutical company; and Royalty Pharma, a leading funder of innovation across the biopharmaceutical industry. Mr. Norden is a former director of Human Genome Sciences, Univision, and Welch Allyn. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services.

What is Gregory Norden's net worth?: The estimated net worth of Gregory Norden is at least $3.92 million as of March 7th, 2023. Mr. Norden owns 23,800 shares of Zoetis stock worth more than $3,923,192 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Norden may own. Learn More about Gregory Norden's net worth.
How do I contact Gregory Norden?: The corporate mailing address for Mr. Norden and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Gregory Norden's contact information.
Has Gregory Norden been buying or selling shares of Zoetis?: Gregory Norden has not been actively trading shares of Zoetis over the course of the past ninety days. Most recently, Gregory Norden sold 4,500 shares of the business's stock in a transaction on Friday, November 5th. The shares were sold at an average price of $216.07, for a transaction totalling $972,315.00. Learn More on Gregory Norden's trading history.
Who are Zoetis' active insiders?: Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO & Director), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 3,132 shares worth more than $547,983.01. The most recent insider tranaction occured on April, 18th when EVP Roxanne Lagano sold 923 shares worth more than $139,529.91. Insiders at Zoetis own 0.2% of the company. Learn More about insider trades at Zoetis.
Information on this page was last updated on 4/18/2024.

Gregory Norden Insider Trading History at Zoetis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/5/2021	Sell	4,500	$216.07	$972,315.00

Gregory Norden Buying and Selling Activity at Zoetis

Zoetis Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $164.84

$163.53

$166.39

50 Day Range

MA: $178.52

$163.52

$194.45

2 Week Range

Now: $164.84

$144.80

$200.53

Volume

6,184,068 shs

Average Volume

2,552,173 shs

Market Capitalization

$74.37 billion

P/E Ratio

30.99

Dividend Yield

1.03%

Beta

0.89

Most People Are Dead Wrong.

From Brownstone Research | Ad